The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice

Current Medical Research and Opinion

Volumn 22, Issue 2, 2006, Pages 335-341

  Schreiber, Stephan A ^a   Russmann, Anika ^a  

^a NONE   (Germany)

Author keywords

Educational programme; Insulin glargine; Oral antidiabetic agent; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONSULTATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; EDUCATION PROGRAM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; CLINICAL PRACTICE; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; INSULIN; MALE; MEDICAL AUDIT; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 33645738846     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80468     Document Type: Article

References (24)

1. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [UK Prospective Diabetes Study Group]. Lancet 1998;352:837-53
2. Porte Jr D, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001;50(Suppl 1): S160-S163
3. Riddle M. Timely addition of insulin to oral therapy for Type 2 diabetes. Diabetes Care 2002;25:395-6
4. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes [HOE 901/3002 Study Group]. Diabetes Care 2000;23:1130-6
5. Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. Horm Metab Res 2003;35:189-96
6. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. New Engl J Med 1992;327:1426-33
7. Rosenstock J, Schwartz S, Clark CJ, et al. Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
8. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26:S18-S24
9. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-48
10. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
11. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67
12. Mudaliar S, Edelman SV. Insulin therapy in Type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:935-82
13. Brown J, Harris SB, Webster-Bogaert S, et al. The role of patient, physician and systemic factors in the management of Type 2 diabetes mellitus. Fam Pract 2002;19:344-9
14. Rubin R, Peyrot M, Saudek CD. Effect of diabetes education on self-care, metabolic control, and emotional well-being. Diabetes Care 1989;12:673-9
15. Graziani C, Rosenthal M, Diamond J. Diabetes education program use and patient-perceived barriers to attendance. Fam Med 1999;31:358-63
16. Tankova T, Dakovska G, Koev D. Education of diabetic patients - a one year experience. Patient Educ Couns 2001;43:139-45
17. Matteucci E, Giampietro O. Closing the gap between literature and practice: evaluation of a teaching programme (in the absence of a structured treatment) on both Type 1 and Type 2 diabetes. Diabetes Nutr Metab 2003;16:298-305
18. de Sonnaville JJ, Bouma M, Colly LP, et al. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40:1334-40
19. Sarkadi A, Rosenqvist U. Experience-based group education in Type 2 diabetes: a randomised controlled trial. Patient Educ Couns 2004;53:291-8
20. Riddle M, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetes patients. Diabetes Care 2003;26:3080-6
21. Riddle M, Stewart J, Bradley C. The treat-to-target trial: randomized addition of insulin to oral therapy of Type 2 diabetes. Diabetologia 2000;43:3080-6
22. Sinha AFC, Tsalamandris C, Panagiotopoulos S, et al. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med 1996; 13:40-6
23. DCCT. Influence of intensive diabetes treatment on body weight and composition of adults with Type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711-21
24. Schreiber SA, MD, Russann A. Insulin glargine and educational intervention in patients with Type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes 2006:114:in press